Does Mounjaro Cause Muscle Loss? How to Protect Muscle and Bone

A woman with short grey hair holds a yellow kettlebell at her chest in a deep squat in a bright gym with tall windows and a rack of dumbbells behind.
In this article
  1. What the trial actually measured
  2. Why do you lose muscle on Mounjaro?
  3. How to protect muscle on Mounjaro
  4. Does Mounjaro affect bone density?
  5. How do you know if you are losing muscle?
  6. Can you regain muscle after Mounjaro, or after 60?
  7. Do supplements help?
  8. What we don't know
  9. Frequently asked questions

Mounjaro has not been shown to act on muscle directly, but losing weight fast on it does cost some, and how much depends on two things you control. In the body-composition study inside the main tirzepatide trial, about three-quarters of the weight lost was fat and a quarter was lean tissue, the same proportions seen with weight loss by diet.1, 15 Lean tissue is not only muscle; the scan's lean figure includes water, glycogen and organ tissue, which is why the headline figure overstates the muscle. The two levers with trial evidence are resistance exercise, which protected fat-free mass with moderate certainty across 25 diet trials, and protein, which kept about 0.4 kg more across 24; neither has been tested on tirzepatide.2, 3, 4, 5

  • The figure: roughly 25% of weight lost is lean tissue on tirzepatide, similar to dieting; a 2026 pooled analysis of GLP-1 and related medicines put it at about 28%, and whether that shows in strength is uncertain
  • What protects it: protein spread across the day, resistance training, not under-eating
  • Bone: fast weight loss by any method is expected to lower bone density a little; weight-bearing exercise, protein, calcium and vitamin D limit it

Sources checked on 5 November 2026.

What the trial actually measured

SURMOUNT-1 was tirzepatide's main weight-management trial. A subgroup of 160 people had DXA scans at the start and after 72 weeks.1 Of the weight those on tirzepatide lost, about three-quarters was fat mass and a quarter lean mass. The proportion was consistent across sex, age and weight-loss subgroups, and similar to what the placebo group lost from their smaller weight loss. Six of the eight authors were employees and shareholders of the manufacturer.1

Two readings of that figure are common and both are wrong. "You lose a quarter of your muscle" is wrong: lean mass includes water, glycogen and organ tissue, and the quarter is of the weight lost, not of your muscle. "The drug melts muscle" is wrong: the placebo group lost lean mass in the same proportion. The duller truth is that losing weight fast costs some muscle unless you act, and the medicine makes losing weight fast easy. This is one chapter of our guide to living well on Mounjaro.

Why do you lose muscle on Mounjaro?

Three likely reasons; what each does to muscle has not been measured on tirzepatide. In a manufacturer-funded trial of 114 adults with overweight or obesity, tirzepatide cut what people ate at a test lunch by about 525 kcal against placebo after three weeks, with less hunger and fewer cravings, so protein intake falls unless you deliberately keep it up, and muscle is rebuilt daily from dietary protein.6 Fatigue is a listed common side effect of the medicine, and tired people train less.18 And you are in a sustained energy deficit, during which the body draws on muscle as well as fat for fuel.

How to protect muscle on Mounjaro

Protein, 1.2 to 1.6 g per kilogram of body weight, spread across the day. In 24 diet trials the higher-protein groups kept about 0.4 kg more fat-free mass, a modest effect, and no trial has yet tested protein in people on the medicine; one eight-person study, part-funded by the US beef industry, favoured about 30 g at each of three meals over one large dinner.2, 4, 5, 7 How much protein you need on Mounjaro has the range and the weight-basis caveat.

Resistance training, two or three times a week. In a systematic review of adults losing weight by diet, adding resistance exercise reduced the loss of fat-free mass (moderate certainty), and in older adults it largely prevented it.3, 8 It does not need a gym: squats, press-ups, step-ups and band or dumbbell rows, progressing the load over weeks.

Do not under-eat. Days under about 1,200 kcal, the NHS threshold for a very low calorie diet, deepen the deficit and push the body towards muscle for fuel.12 What to eat on Mounjaro covers eating enough; why has my weight loss stalled covers why eating less is the wrong answer.

Does Mounjaro affect bone density?

Fast weight loss by any method is expected to lower bone mineral density a little, because bone responds to the load it carries and a lighter body carries less; that is physiology, and the trials below measured it on these medicines.9, 16, 17 Whether GLP-1 medicines add anything beyond weight loss is unsettled, and the pooled analyses disagree with each other: a 2026 analysis of 60 studies in more than 1.2 million people found no effect on bone density or fractures, while a 2026 analysis limited to placebo-controlled trials (eleven of older medicines and one of semaglutide at 1.0 mg) found lumbar-spine density about 0.02 g/cm2 lower on the medicine, moderate certainty, with no difference at the hip; in a Danish placebo-controlled trial of semaglutide at that dose, 64 adults at raised fracture risk, mostly postmenopausal women, lost about 0.02 g/cm2 more at the spine and hip than on placebo over a year while losing more weight (regional health and foundation funding; the maker supplied the drug).9, 16, 17 In one trial of 195 adults liraglutide alone lowered hip and spine density more than exercise.10 No placebo-controlled bone trial of tirzepatide, or of semaglutide at the weight-management dose, had been published when that analysis searched, in May 2026.16 The protective measures are the same as for muscle, plus the calcium and vitamin D that a narrowed diet often loses. The NHS advises everyone to consider a daily 10 microgram vitamin D supplement in autumn and winter;13 the authorised wording is that it contributes to the maintenance of normal bones. If you are post-menopausal, have a family history of osteoporosis or have had a fracture from a minor fall, mention the weight loss to your GP, who may consider a bone-density check.

How do you know if you are losing muscle?

Not from the scales, including body-composition scales, which swing with hydration. The signs are functional: shopping bags feel heavier, your grip on a jar is weaker, you feel weak rather than light. A monthly tape measure around the upper arm and thigh is more honest than the scales. If strength is falling while weight falls, protein and resistance work are behind; if it holds or rises, you are losing mostly fat.

Can you regain muscle after Mounjaro, or after 60?

Yes to both. Muscle responds to resistance training at every age; the review showing lean mass preserved during dieting was in older adults.8 Coming off the medicine, this matters doubly, because weight regained without training can come back as fat; what happens when you stop covers it.

Do supplements help?

Protein powder, instead of a meal you cannot face, delivers 20 to 30 g of protein without appetite. Collagen vs whey protein and collagen with resistance training cover what each does. Creatine has authorised UK wording for improving performance in short bursts of high-intensity exercise and, for adults over 55, for enhancing the effect of resistance training on muscle strength; it is relevant if you train. Magnesium contributes to normal muscle function, and intake often falls on a shrunken diet.

What we don't know

  • Whether tirzepatide changes muscle quality in people without diabetes. One MRI substudy of 246 adults with type 2 diabetes (190 on tirzepatide, the rest on insulin) found less fat inside the thigh muscle after 52 weeks on tirzepatide, a fall of 0.36 percentage points, more than weight loss alone would predict, while thigh muscle volume fell by 0.64 litres, in line with the weight lost; strength was not measured, the analysis was post hoc and the comparison was with insulin.14
  • The best protein dose on the medicine. The 1.2 to 1.6 g range comes from weight loss by diet; the first randomised trial of protein and resistance exercise in people starting semaglutide or tirzepatide (232 people, six months) has published its protocol only.5
  • Long-term bone effects. The trials ran up to 88 weeks. The 2026 pooled analysis of 60 studies found no effect on fractures, but long-term fracture data on these medicines are thin.9

Frequently asked questions

Does Mounjaro cause muscle loss?

It has not been shown to act on muscle directly. About a quarter of the weight lost on it is lean tissue, the same as with dieting, and lean tissue includes water and organ tissue as well as muscle. Protein and resistance training shift the ratio towards fat.1, 3

How do I limit muscle loss on Mounjaro?

In diet trials, 1.2 to 1.6 g of protein per kilogram a day and resistance training two or three times a week kept more lean mass. Neither has been tested on tirzepatide.3, 4

Does Mounjaro cause bone loss?

Fast weight loss by any method is expected to lower bone density a little. The pooled analyses disagree: one of 60 studies in more than 1.2 million people found no separate effect, one of placebo-controlled trials found a small fall at the spine, and no placebo-controlled bone trial of tirzepatide had been published by May 2026. Weight-bearing exercise, protein, calcium and vitamin D are the protective measures.9, 16

Why am I losing weight so fast on Mounjaro?

Because appetite has fallen further than you have noticed. When it outruns protein and resistance training, more of it is muscle. If the pace worries you, raise food and protein first and tell your prescriber.

Do Wegovy, Ozempic and other GLP-1 medicines cause muscle loss too?

Across 28 pooled comparisons lean mass fell more on GLP-1 medicines than on placebo, and a second 2026 analysis put lean tissue at about 28% of the weight lost, similar to dieting. A third 2026 pooled analysis, of 20 randomised trials in 15,782 adults, put the lean share of weight lost at about 25 to 39% across semaglutide, tirzepatide and liraglutide, statistically no different from lifestyle programmes (26%), and lowest, 17.5%, when the lifestyle programme included resistance training.15 The trials differ too much to rank the medicines against each other; the protection is the same two levers.9, 11

Sources

  1. Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025. Scan substudy of a randomised trial, 160 adults, 72 weeks; manufacturer-funded. PubMed 39996356.
  2. Leidy HJ, et al. The role of protein in weight loss and maintenance. American Journal of Clinical Nutrition, 2015. Narrative review of meta-analyses and feeding trials; funding not stated on PubMed. PubMed 25926512.
  3. Binmahfoz A, et al. Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss: a systematic review and meta-analysis. BMJ Open Sport and Exercise Medicine, 2025. Pooled analysis, 25 randomised trials; no conflicts declared, funding not stated on PubMed. PubMed 40909191.
  4. Wycherley TP, et al. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 2012. Pooled analysis, 24 trials, 1,063 adults; non-commercial funding. PubMed 23097268.
  5. Alawadhi AA, et al. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. BMJ Open, 2026. Trial protocol, 232 adults, 6 months; no competing interests declared. PubMed 42020128.
  6. Martin CK, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature Medicine, 2025. Randomised phase 1 trial, 114 adults, 6 weeks; manufacturer-funded, eleven of nineteen authors its employees. PubMed 40555748.
  7. Mamerow MM, et al. Dietary protein distribution positively influences 24-h muscle protein synthesis in healthy adults. Journal of Nutrition, 2014. Crossover feeding trial, 8 adults, 7 days per diet; part-funded by the US beef industry and US government grants. PubMed 24477298.
  8. Sardeli AV, et al. Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: a systematic review and meta-analysis. Nutrients, 2018. Pooled analysis, 6 randomised trials in older adults, 12 to 24 weeks; no conflicts declared. PubMed 29596307.
  9. Beaudart C, et al. GLP-1 receptor agonists and musculoskeletal outcomes: a systematic literature review and meta-analysis. Drugs, 2026. Pooled analysis, 60 studies, 1,250,717 people; funding not stated on PubMed. PubMed 42730869.
  10. Jensen SBK, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Network Open, 2024. Secondary analysis of a randomised trial, 195 adults, 52 weeks; authors declare industry fees. PubMed 38916894.
  11. Jobanputra R, et al. The effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on lean body mass in humans: a systematic review and meta-analysis of randomised controlled trials. Diabetes/Metabolism Research and Reviews, 2026. Pooled analysis, 36 randomised trials; authors declare industry fees. PubMed 42319968.
  12. NHS. Obesity: treatment. Page last reviewed 29 April 2026. nhs.uk.
  13. NHS. Vitamin D. Page last reviewed 3 August 2020 (review overdue). nhs.uk.
  14. Sattar N, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes and Endocrinology, 2025. Post hoc MRI analysis of a randomised open-label trial, 246 adults with type 2 diabetes, 52 weeks, comparator insulin degludec; manufacturer-funded, three authors its employees and two employees of the imaging company with consulting fees from the manufacturer. PubMed 40318682.
  15. Eisa N, Barood O. Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials. Diabetes, Obesity and Metabolism, 2026. Pooled analysis, 20 randomised trials, 15,782 adults, DXA or MRI; no conflicts on record, funding not stated on PubMed. PubMed 41877354.
  16. Safargar M, et al. The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: a systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents. Bone, 2026. Pooled analysis of 12 placebo-controlled trials, 11 of exenatide, dulaglutide or liraglutide and one of semaglutide 1.0 mg; lumbar spine 3 trials, 222 people; no competing interests. PubMed 42971377.
  17. Hansen MS, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine, 2024. Randomised placebo-controlled trial, 64 adults, 52 weeks; funded by a regional health authority, the semaglutide maker's foundation and a private foundation; the maker supplied the drug and placebo. PubMed 38737002.
  18. Tirzepatide Summary of Product Characteristics, section 4.8 (fatigue common in the weight-management trials), electronic medicines compendium, date of revision of the text 29 August 2026. medicines.org.uk.

Spotted something out of date? Email support@wellgard.co.uk with the page address and the sentence.

This article is general information, not medical advice. Mounjaro is a prescription medicine: follow your prescriber's instructions, and speak to your GP before starting a new exercise programme if you have a heart, joint or bone condition.